Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues-Reference-Cited by-同舟云学术

Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues

Published:2023-01 Issue:1 Volume:62 Page:66-70
ISSN:1028-4559
Container-title:Taiwanese Journal of Obstetrics and Gynecology
language:en
Short-container-title:Taiwanese Journal of Obstetrics and Gynecology

Author:

Kim Eun Taeg,Jeong Ha Eun,Yoon Hyung Joon,Kim Ki Hyung,Suh Dong Soo

Funder

Pusan National University Hospital

Texas Biomedical Research Institute

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology

Reference28 articles.

1. Hereditary ovarian cancer;Prat;Hum Pathol,2005

2. Hereditary ovarian cancer: not only BRCA 1 and 2 genes;Toss;BioMed Res Int,2015

3. BRCA1 and BRCA2: different roles in a common pathway of genome protection;Roy;Nat Rev Cancer,2012

4. Cancers associated with BRCA 1 and BRCA 2 mutations other than breast and ovarian;Mersch;Cancer,2015

5. High incidence of BRCA1–2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma;Biron-Shental;Eur J Surg Oncol,2006

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cervical cancer: Part II the landscape of treatment for persistent, recurrent and metastatic diseases (I);Taiwanese Journal of Obstetrics and Gynecology;2024-09

2. Besides the front-line maintenance therapy, is any positive impact of poly (ADP-ribose) polymerase (PARP) inhibitors on recurrent high-grade ovarian cancer?;Taiwanese Journal of Obstetrics and Gynecology;2024-09

3. Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part II;Journal of the Chinese Medical Association;2024-06-19

4. BRCA mutation in Vietnamese prostate cancer patients: a mixed cross-sectional study and case series;Oncologie;2024-02-26

5. Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen;Taiwanese Journal of Obstetrics and Gynecology;2024-01